US sales ok what about the rest of the World EMA filing for the approval in Europe also expected this year . What a about potential Upfront payments from potential Partners which could be higher than the entire valuation of CLSD (Market cap $42 Million) .Looks like your math is not good but i know what your intention is hehe .
Again if you want cheap shares then i wouldnt wait to long hehe. CLSD is trading way below Cash and FDA approval could come by mid year with priority review but we could have a very nice run up ahead of the FDA decision thats what underpriced biotechs usually do.Oh and there is nothing personal in my previous post .
News 
Market Data 
Discover 
